

Associate editor: P. Molenaar

Sex dimorphism in cardiac pathophysiology: Experimental findings, hormonal mechanisms, and molecular mechanisms

Xiao-Jun Du*, Lu Fang, Helen Kiriazis

Experimental Cardiology Laboratory, Baker Heart Research Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia

Abstract

The higher cardiovascular risk in men and post-menopausal women implies a protective action of estrogen. A large number of experimental studies have provided strong support to this concept. However, the recent clinical trials with negative outcomes regarding hormone replacement therapy call for “post hoc” reassessment of existing information, models, and research strategies as well as a summary of recent findings. Sex steroid hormones, in particular estrogen, regulate numerous processes that are related to the development and progression of cardiovascular disease through a variety of signaling pathways. Use of genetically modified models has resulted in interesting information on diverse actions mediated by steroid receptors. By focusing on experimental findings, we have reviewed hormonal, cellular, and signaling mechanisms responsible for sex dimorphism and actions of hormone replacement therapy and addressed current limitations and future directions of experimental research. © 2005 Elsevier Inc. All rights reserved.

Keywords: Heart disease; Estrogen; Androgen; Steroid hormone receptor; Sex difference

Abbreviations: β -AR, β -adrenergic receptor; ACE, angiotensin-converting enzyme; ANP, atrial natriuretic peptide; AR, androgen receptor; AT, angiotensin receptor; E2, 17 β -estradiol; ECM, extracellular matrix; ER, estrogen receptor; ERE, estrogen response element; ERR, estrogen-related receptors; ERT, estrogen replacement therapy; HSP, heat shock protein; I/R, ischemia/reperfusion; LPL, lipoprotein lipase; LV, left ventricle or left ventricular; MAPK, mitogen-activated protein kinase; MHC, myosin heavy chain; MI, myocardial infarction; MMP, matrix metalloproteinases; NCX, Na⁺/Ca²⁺ exchanger; NF- κ B, nuclear factor- κ B; NO, nitric oxide; NOS, nitric oxide synthase; NPR-A, natriuretic peptide receptor-A; PKG, protein kinase G; PGC-1, PPAR α -activated receptor γ coactivator-1; PPAR, peroxisome proliferator-activated receptor; RAS, renin-angiotensin system; SHBG, steroid hormone binding globulin; SHR, spontaneously hypertensive rats; SR, sarcoplasmic reticulum; TGF- β , transforming growth factor- β ; VSMC, vascular smooth muscle cells.

Contents

1. Introduction	435
2. Sex dimorphism in cardiac pathophysiology	436
2.1. Myocardial hypertrophy	436
2.2. Cardiac fibrosis	436
2.3. Cardiac ischemia, infarction, and post-infarct healing	436
2.4. Electrophysiology and arrhythmogenesis	437
2.5. Altered gene expression in disease and aging	438
2.6. Cardiomyopathy and myocarditis	438
3. Hormonal mechanisms	439
3.1. 17 β -Estradiol and its bioactive metabolites	440
3.2. Selective estrogen receptor modulators and phytoestrogens	442
3.3. Androgens	443
4. Steroid hormone receptors in the cardiovascular system	445
4.1. Estrogen receptors and estrogen-related receptors	446

* Corresponding author. Tel.: +61 3 9276 2028; fax: +61 3 8532 1100.

E-mail address: xiaojun.du@baker.edu.au (X.-J. Du).

4.2.	Non-nuclear localized estrogen receptors and signaling mechanisms	447
4.3.	Androgen receptors	447
5.	Potential signaling mechanisms	448
5.1.	Ion channels, ion exchangers, and modulators	448
5.1.1.	Voltage-gated K ⁺ channels and K _{ATP} channels.	448
5.1.2.	Ca ²⁺ channels, sarcoplasmic reticulum, Ca ²⁺ uptake and storage	449
5.1.3.	Na ⁺ /H ⁺ exchanger, Na ⁺ /Ca ²⁺ exchanger, and Na ⁺ /K ⁺ -ATPase.	450
5.1.4.	Relevant findings derived from gene-targeted models	450
5.2.	Renin-angiotensin system and angiotensin receptors	451
5.3.	Nitric oxide synthase	451
5.4.	Hypertrophic signaling	452
5.4.1.	Pro-hypertrophic signaling	452
5.4.2.	Anti-hypertrophic signaling via cGMP/protein kinase G pathway	453
5.5.	Signaling pathways mediating cell protection.	454
5.5.1.	Heat shock proteins	454
5.5.2.	Phosphoinositide 3-kinase/serine–threonine kinase Akt pathway	454
5.5.3.	Insulin growth factor-1 and receptors	454
5.5.4.	Telomerase	455
5.6.	Peroxisome proliferator-activated receptor α -activated receptor γ coactivator-1/peroxisome proliferator-activated receptor pathway.	455
5.7.	Matrix remodeling and function of cardiac fibroblasts	456
5.8.	Inflammatory and coagulatory markers, oxidative stress, and post-injury responses	457
5.8.1.	Inflammation and coagulatory markers	457
5.8.2.	Oxidative stress	459
5.8.3.	Healing process and angiogenesis post-cardiovascular injury	459
5.9.	Cardiac signaling of the sympathoadrenergic system	459
6.	Concluding comments	461
6.1.	“Post hoc” analyses of experimental versus clinical findings.	461
6.2.	Future research directions.	462
	Acknowledgments	464
	References	464

1. Introduction

Sex-related differences in cardiovascular morbidity and mortality have long been recognized. The most striking difference is a 10- to 15-year delay in the prevalence of coronary artery disease in women than men. Under conditions of heart diseases, although younger women have less favorable outcomes than men after myocardial infarction (MI), prognosis is much worse in men than in women for heart failure (Vaccarino et al., 2001). Women with pressure overload have better preserved the left ventricular (LV) function but with a more marked concentric hypertrophy, whereas men tend to develop eccentric hypertrophy with LV dilatation (Aurigemma & Gaasch, 1995). Risk of sudden cardiac death is also lower in women than men according to the Framingham study (Kannel & Schatzkin, 1985).

Epidemiological studies show that men and post-menopausal women are at a higher risk for cardiovascular diseases than pre-menopausal women, suggesting that female steroid hormones, in particular estrogen, are cardioprotective (Mendelsohn & Karas, 1999; Dubey & Jackson, 2001b). Although changes in lipid profile occur depending on menstrual status or the use of hormone replacement therapy, direct actions of sex steroids on the heart and blood vessels account for about 50–70% of overall beneficial effects. These observations have

resulted in estrogen replacement as the most frequently prescribed therapy to post-menopausal women in the last 2 decades. Indeed, cardiovascular protection by estrogen replacement therapy (ERT) in post-menopausal women has been suggested by numerous observational studies as well as large-scale clinical trials (Grodstein et al., 1997, 2000; Greendale et al., 1999) and by experimental studies. However, recent large-scale randomized trials (Grady et al., 2002; Manson et al., 2003) have provided evidence that ERT might actually increase the risk of cardiac disease.

While these findings are in contrast to those from the majority of observational clinical studies and animal studies, and are therefore surprising to researchers, they do suggest a fragmented knowledge on the mechanisms underlying sex differences in cardiovascular disease and perhaps misinterpretation of existing literature of clinical and experimental research. This calls for a timely overview of the database of experimental research on the hormonal and molecular mechanisms mediating sex dimorphism. This review is aimed to provide a comprehensive summary of experimental data on sex dimorphism in cardiac pathophysiology, lipid-independent hormonal mechanisms, sex steroid receptors, and molecular mechanisms that mediate sex differences, particularly recent findings in a range of in vitro and in vivo models.

Download English Version:

<https://daneshyari.com/en/article/2564072>

Download Persian Version:

<https://daneshyari.com/article/2564072>

[Daneshyari.com](https://daneshyari.com)